Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Conference Presentation (March 2026)
11 slides from Orion Oyj Class A's conference presentation, March 2026
Slide 1: Orion Pharma: Building shareholder value
Orion Pharma Building shareholder value
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Orion in brief
Orion in brief Established in 1917 in Finland Proven track record in innovation R&D focus on oncology and pain Operations in >35 countries R&D sites in Finland, UK and USA Production sites in Finland, France and Belgium FINANCIALS 2025 NET SALES OPERATING PROFIT 4,000 EUR 1,890 million EUR 632 milli
Slide 4: Our diversified and balanced businesses
Our diversified and balanced businesses Innovative Generics and Branded Products Animal Health Fermion Medicines Consumer Health Respiratory Companion API Portfolio CNS 300+ products animals & manufacturing highlights Women’s Health livestock & CDMO Nordics & Geographies Global Europe & APAC Global
Slide 5: With strong track record in delivering financial results, we have entered a new growth era
With strong track record in delivering financial results, we have entered a new growth era Net sales Operating profit (EUR million) (EUR million) 2,000 1,890 700 +12.1% 632 183 600 1,542 1,500 183 1,341 134 500 1,190 440 234 417 1,051 1,078 1,041 32 400 51 42 3 1,000 134 +15.5% 280 234 1,706 300 253
Slide 6: Financial objectives
Financial objectives Strategy period 2024–2028 Net sales Operating profit CAGR ≥8%1 To grow faster than net sales1,2 Equity ratio Return on equity (ROE) ≥50% ≥25% Dividend Annually increasing dividend – payout ratio 50%–100% 1 Base year 2023 6 Investor Presentation © Orion Corporation 2 Without EUR
Slide 7: Investment case – key themes
Investment case – key themes Growth Stability Innovative Medicines business Branded Products, Generics and division and Nubeqa® driving the Consumer Health, and Animal Health growth. Further opportunities in business divisions are stable, profitable R&D pipeline. and generate healthy cash flow. Inno
Slide 8: Orion's key clinical development pipeline
Orion’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication (or modality for pre-clinical assets) Preclinical Phase I Phase II Phase III ARASTEP (darolutamide) BCR (prostate cancer) DASL-HiCaP (darolutamide) (Neo-)Adjuvant prostate cancer OMAHA-003 (opevesostat) (lat
Slide 9: Expected pipeline news flow
Expected pipeline news flow LEVEL Phase 3 primary ARASTEP Phase 3 primary DASL-HiCaP Phase 3 estimated completion Q3 20261,2 completion Q3 20271,2 primary completion Q1 20281,2 Initiation of a Phase 2 OMAHA-015 Phase 2 primary OMAHA-004 Phase 3 primary combination trial with completion Q4 20271,2 co
Slide 10: Outlook for 2026
Outlook for 2026 Net sales EUR 1,900 million–EUR 2,100 million Operating profit EUR 550 million–EUR 750 million 10 Investor Presentation © Orion Corporation
Slide 11: Q&A
Q&A 11 Investor Presentation © Orion Corporation